Avalo Therapeutics, Inc.

The momentum for this stock is not very good. Avalo Therapeutics, Inc. is not a good value stock. Avalo Therapeutics, Inc. is not a good growth stock. Avalo Therapeutics, Inc. is not very popular among insiders. Avalo Therapeutics, Inc. is a mediocre stock to choose.

News

Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8%

Ticker Report Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) traded up 7.8% during mid-day trading on Monday . The stock traded as high as $8.28 and last traded at $8.15. 19,040 shares changed hands...\n more…

KaliVir Immunotherapeutics appoints CFO as cancer treatment company prepares for clinical trials

Bizjournals.com - Health Care News Schond Greenway previously served as CFO of psychedelic therapy startup MindMed, as well as biotech firm Avalo Therapeutics.\n more…

Avalo Announces Participation in September Investor Conferences

Globe Newswire WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the...\n more…

Avalo Therapeutics trading resumes

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Avalo Therapeutics trading halted, volatility trading pause

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July

Ticker Report Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 58,600...\n more…